规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
---|---|---|---|---|---|---|---|---|---|
g | ¥ ǑǬŰǬǬ | > 0 | > 0 | 2 | 2 | ¥ ǑǬŰǬǬ | - + | ||
5g | ¥ IJȰŰǬǬ | > 0 | > 0 | -- | 6 | 6 | 2 | ¥ IJȰŰǬǬ | - + |
0g | ¥ ƈŻŰǬǬ | > 0 | > 0 | 2 | 9 | 9 | ¥ ƈŻŰǬǬ | - + | |
25g | ¥ ǟƈƹŰǬǬ | > 0 | > 0 | -- | > 0 | > 0 | 0 | ¥ ǟƈƹŰǬǬ | - + |
00g | ¥ DžƤǟŰǬǬ | > 0 | > 0 | -- | > 0 | > 0 | 8 | ¥ DžƤǟŰǬǬ | - + |
500g | ¥ ǑǬIJǑŰǬǬ | 4 | > 0 | -- | -- | ¥ ǑǬIJǑŰǬǬ | - + | ||
kg | ¥ ƤDžŻǬŰǬǬ | 2 | 8 | -- | -- | -- | -- | ¥ ƤDžŻǬŰǬǬ | - + |
大货 | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
44.48
[]. Dai, Y., Hartandi, K., Ji, Z., et al al. Discovery of N-(4-(-amino-H-indazol-4-yl)phenyl)-N -(2-fluoro-5-methylphenyl)urea (ABT-869), a -aminoindazole-based ORALLY ACTIVE MULTITARGED Receptor Tyrosine Kinase Inchibitorj. Chem.50 (7) 584-597 (2007).
[2]. Paraiso, KHT, HAARBERG, He, Wood, E., ET Al.The HSP9 0 Inhibitor XL888 Overcomes Braf Inchibitor Resistance Mediated Through diverse mechanisms Clin. Cancer Res. 8(9) 2502-254(202).
H5-H9-H5
P26-P264-P27-P280-P02+P52-P04+P40-P62-P405-P50